AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02710630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate tablet D1
Study NCT02710630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate tablet C1
Study NCT02710630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate tablet B1
Study NCT02710630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate tablet A1
Study NCT02710630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran etexilate capsule
Study NCT03681301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality simulator
Description: Additional self-directed learning and practice using virtual reality simulator
Study NCT02409485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Skill-Training (CST)
Description: Patients and partners each receive a workbook and 6 one-hour telephone sessions with a Masters level trained interventionist. Manual content is tailored based on role (patient or partner). Couples participate together via speaker phone for half the sessions and patients and partners receive separate (individual) intervention calls for the other half of the sessions.
Study NCT03934229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily intake of study product
Description: Daily intake of Bifidobacterium animalis ssp. lactis 420 or placebo for a 6-month period
Study NCT03934229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Daily intake of study product
Description: Daily intake of Bifidobacterium animalis ssp. lactis 420 or placebo for a 6-month period
Study NCT00995449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB003
Description: KB003 IV x5 doses
Study NCT00995449 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo IV x5 doses
Study NCT00047463 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure (CPAP)
Description: a mask treatment for sleep apnea
Study NCT00047463 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-CPAP
Description: Placebo-CPAP
Study NCT02421991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Delivered Intervention
Study NCT02421991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Delivered Intervention
Study NCT04233814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
Description: LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.
Study NCT04233814 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Matching placebo is micronized lactose powder administered by inhalation through a dry powder inhaler.
Study NCT04067141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: Contact Lens
Study NCT04067141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nelfilcon A
Description: Contact Lens
Study NCT01259986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: Laser treatment of using 635 nm laser with a dose of 3.0 J/cm\^2 to small area (2cm x 2cm) of vitiligo once to twice a week for a total of 12 weeks.
Study NCT00393445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 control
Description: intravenous infusion of GLP-1
Study NCT00393445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 and Exendin(9-39) 300
Description: intravenous infusion of exendin(9-39) at 300 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
Study NCT00393445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline control
Description: intravenous infusion of saline
Study NCT00393445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 and Exendin(9-39) 600
Description: intravenous infusion of exendin(9-39) at 600 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
Study NCT00393445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 and Exendin(9-39) 900
Description: intravenous infusion of exendin(9-39) at 900 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
Study NCT00393445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 and Exendin(9-39) 1200
Description: intravenous infusion of exendin(9-39) at 1200 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
Study NCT00058305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Description: Given IV
Study NCT00058305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00058305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04321460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LRG-002
Description: Capsules containing live lyophilized probiotic bacteria of Lactobacillus genus
Study NCT04321460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing placebo
Study NCT01368458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conversion to Antipsychotic Monotherapy
Description: Patients assigned to the antipsychotic monotherapy group will have the dosage of their secondary (i.e. one due to be reduced) antipsychotic reduced by decreased by approximately 1/3 every 3 weeks. Dosage of the primary antipsychotic will be left unchanged.
Study NCT00642304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [C.E.R.A.]
Description: Methoxy polyethylene glycol-epoetin beta is administered SC every four week up to Week 20.The starting dose is 120, 200 or 300 mcg based on the dose of darbepoetin alfa or epoetin beta participants shall be receiving in the week preceding the study start. Further dose adjustment during the study depending on the hemoglobin (Hb) values.
Study NCT03617809 — intervention group
Intervention type: PROCEDURE
Intervention: Preoperative warming
Description: The prewarming time will not be decided by the clinical investigator. Prewarming time will depend on the time the patient has to wait before entering in the operating room.
Study NCT01709227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output \<1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output >1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
Study NCT01709227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis
Description: Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management and discontinuation will be directed by CICU attending and Nephrology service.
Study NCT04695691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera Laser System
Description: Subjects will receive laser treatments
Study NCT06270121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living-lab digital intervention group
Description: Older adults will receive individualized daily health feedback via the mobile applications, which will be shared with caregivers. They will also receive support for health emergency by the platform sending automatic emergency push alarm to community and family caregivers.
Study NCT04589559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback Training
Description: First, participants are taught how to do relaxed, abdominal breathing. Second, they are taught how to breathe at a slow rate of 0.1 Hz (i.e., one completed breath cycle every 10 seconds). Third, they are taught how to monitor their heart rate variability (HRV) in real time using the smartphone app, which receives data wirelessly via Bluetooth from the heart rate monitor. Participants are instructed that their goal is to increase their HRV during the three weeks of at-home practice.
Study NCT03217136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam
Description: Ceftolozane 20 mg/kg (maximum 1 g) and tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 5 to 14 days.
Study NCT03217136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 10 mg/kg (maximum 1.5 g/day) administered IV every 8 hours for between 5 to 14 days. Participants ≤ 28 days old, start with a loading dose of 15 mg/kg; then if ≤ 2 kg are dosed 7.5 mg/kg/ every 12 hours; or if > 2 kg are dosed 10 mg/kg every 8 hours.
Study NCT03217136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 5 to 14 days.
Study NCT03217136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Metronidazole
Description: Placebo for metronidazole administered IV every 8 hours for between 5 to 14 days.
Study NCT02487979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02703779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be given to Group B participants by injection under the skin 11 days and 8 days before stem cell collection.
Study NCT01183793 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Barium follow-through and MR-enterography
Description: Assessment of the lack of difference between surgical and MR enterography small bowel length measurement with a comparison sample test
Study NCT02418260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bridge Plate osteosynthesis
Description: Trough two anterior skin incisions, the 4.5mm narrow DCP plate will be placed on the anterior surface of the humerus and, after indirect reduction, it will be fixed to the bone with 2 proximal and 2 distal screws.
Study NCT02418260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Locked intramedullary nail osteosynthesis
Description: Trough an anterolateral approach to the shoulder, the supraspinatus tendon will be longitudinally splited allowing the insertion of the intramedullary nail.
Study NCT02418260 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction and plate osteosynthesis
Description: Trough an posterior or anterolateral approach, the fracture will be directly reduced and fixed with a broad DCP 4.5mm plate.
Study NCT02703779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.
Study NCT02703779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.
Study NCT02703779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mozobil
Description: Mozobil will be given to all participants by injection under the skin only if needed per Investigator.
Study NCT02779218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paired Associative Stimulation
Description: Patient with Paired Associative Stimulation only
Study NCT02779218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paired Associative Stimulation + Motor Imagery exercises
Description: Patient with Paired Associative Stimulation + Motor Imagery exercises
Study NCT02779218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo Paired Associative Stimulation + Motor Imagery exercises
Description: Patient with placebo Paired Associative Stimulation + Motor Imagery exercises
Study NCT00002912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00002912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Study NCT00002912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valspodar
Study NCT02703779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mozobil
Description: Mozobil will be given to all participants by injection under the skin only if needed per Investigator.
Study NCT02390973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve Gastrectomy
Study NCT02317575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC
Study NCT02317575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered SC
Study NCT02390973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass
Study NCT02390973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliopancreatic Diversion with Duodenal Switch
Study NCT02390973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical management
Study NCT03660007 — intervention group
Intervention type: PROCEDURE
Intervention: Fresh or frozen embryo transfer IVF
Study NCT04425642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose/Amino acids
Description: If indications for parenteral nutrition appear, it's dose will be calculated according patient's age and weight and will consist of glucose and amino acids solutions. To prevent potential complications of parenteral nutrition, the target dose will be reached by the third day of therapy. It will discontinued, when the patient oral food intake will be more than 60% for three consecutive days.
Study NCT04425642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose/Amino acids/Lipids
Description: If indications for parenteral nutrition appear, it's dose will be calculated according patient's age and weight and will consist of glucose, amino acids and lipid emulsions. To prevent potential complications of parenteral nutrition, the target dose will be reached by the third day of therapy. It will discontinued, when the patient oral food intake will be more than 60% for three consecutive days.
Study NCT02192463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 300 mg (KCR 20%) Medium Release
Study NCT02579291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
Study NCT02579291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bobath
Description: Patients will receive different neuromodulatory interventions based on the Bobath concept with the aim to decrease spasticity on the lower extremity
Study NCT00465166 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound
Description: Lumbar ultrasound from L1-S1, carried out using a portable ultrasound system equipped with a 2-5 MHz curved array probe.
Study NCT04327934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: GnRH antagonist up to 16 days.
Study NCT04327934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: GnRH antagonist up to 16 days.
Study NCT04327934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist + MethylTESTOSTERone 5 MG
Description: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.
Study NCT04327934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist + MethylTESTOSTERone 5 MG
Description: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.
Study NCT01430130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: embrace device
Description: Adhesive bandage/dressing intended to minimize scar formation.
Study NCT03528330 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation with dental implant with internal hexagon connection
Description: All patients will receive an implant with internal hexagon connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W\&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery
Study NCT03528330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation with dental implant with conical connection
Description: All patients will receive an implant with conical connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W\&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery
Study NCT00501449 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.
Study NCT02114502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1
Study NCT02114502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAHA
Description: 1,000 mg by mouth on Days -8 to -3.
Study NCT01223079 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: r-hFSH
Description: r-hFSH dose to be determined by the patient's primary doctor and adjusted according to their response
Study NCT01223079 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: r-hFSH and r-hLH
Description: Patients will begin r-hLH at 300IU/day when there are 2 follicles greater than or equal to 14mm.
Study NCT03459417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine+LA
Description: Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage. patients will receive intrathecal LA 15 mg (3 mL) (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
Study NCT03459417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine+LA+ Mg sulp. 50
Description: Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal +0.5 mg preservative free morphine + magnesium sulphate 50 mg.
Study NCT03459417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine+LA+ Mg sulp. 100
Description: Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal with 0.5 mg preservative free morphine + magnesium sulphate 100 mg.
Study NCT02114502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3.
Study NCT02114502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5.